Answers are grounded in this paper and cite their sources.
The rapid expansion of antibody therapeutics is shifting the clinical bottleneck from drug availability to precise patient selection. We systematically characterize 87 clinically actionable tumor-associated antigens across solid tumors by integrating transcriptomic, proteomic, spatial, and single-cell profiles from more than 32,000 specimens to define expression prevalence, intratumoral heterogeneity, immune contexture, internalization and payload-sensitivity pathways, and translational relevance. We establish ANCHOR, a coordinate reference framework for standardizing patient RNA-seq data, and develop ReSort, a two-tiered scoring system for scalable target prioritization. ReSort enables virtual basket and umbrella trial matching, demonstrates concordance with clinical assays, predicts therapeutic response in patient-derived models, and identifies repurposing opportunities in rare malignancies. We develop an AI-based decision-support agent for antibody trial matching and construct a multimodal feature space integrating tumor- and protein-intrinsic attributes to guide systematic target discovery and prioritization. This work provides a scalable, clinically actionable approach for precision antibody-based therapies and next-generation target development.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: